Myeloid Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

CAMBRIDGE, Mass., April 15, 2024 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage biotechnology company advancing RNA immunotherapies to conquer cancer, today announced its participation at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, taking place virtually April 29-30. 

Daniel Getts, Ph.D., Chief Executive Officer of Myeloid, will participate in a fireside chat on Monday, April 29, 2024, at 11:30 am ET.  Company management will also participate in one-on-one meetings with investors during the event.

About Myeloid Therapeutics

Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases.  Myeloid is headquartered in Cambridge, MA.

For additional information, please visit, and follow us on LinkedIn and X/Twitter.

Investor Contact
Amy Conrad
Juniper Point 

SOURCE Myeloid Therapeutics

Link to original press release can be found here.

BioMediaHub Logo